Illumina, Inc. (ILMN) Stock Valuation — PE Analysis
Medical - Diagnostics & Research · NASDAQ
Current Price
$160.97
PE Ratio (TTM)
28.9x
Intrinsic Value
$218.28
+26.3% margin of safety
COMPETITIVE MOAT
↑NovaSeq X Adoption Fuels Growth
Accelerated adoption of the NovaSeq X platform is driving significant revenue growth. This advanced sequencing technology is becoming a standard for high-throughput genomic analysis.
↑Integrated Software Ecosystem
Illumina's software ecosystem, enhanced by partnerships like IDT, streamlines research workflows. This integration creates stickiness for customers by simplifying complex genomic analysis.
↑Market Leadership in Sequencing
Illumina maintains a dominant position in the sequencing market. Their established infrastructure and brand recognition are difficult for competitors to overcome.
INVESTMENT RISKS
↓Grail Divestiture Uncertainty
The ongoing situation with Grail introduces regulatory and financial uncertainty. Potential divestiture could impact future strategic direction and cash flow.
↓Intensifying Competition
While strong, Illumina faces increasing competition in the genomics space. Emerging technologies and new entrants could challenge their market share.
↓Dependence on Capital Expenditures
The high cost of sequencing instruments and consumables creates a barrier to entry but also means customers have significant capital tied up. This can slow adoption during economic downturns.
Base case
ILMN base case PE valuation
A base case PE valuation for ILMN estimates a fair value of about $218.28 per share, against a current price of $160.97. The model assumes 13.3% annual earnings growth, a 29x target PE multiple, and a 10% discount rate.
Intrinsic Value
$218.28
Margin of safety
+26.3%
Expected annual return
+6.3%
Base case assumptions: 13.3% annual earnings growth, 29x target PE, 10% discount rate, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the ILMN PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Illumina, Inc. respond.
Open PE Calculator for ILMNCompany Overview
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Financial Metrics — ILMN PE Stock Valuation Data
PE Ratio (TTM)
28.9x
PEG Ratio
0.22
Earnings Yield
3.46%
ROE (TTM)
34.0%
Revenue/Share (TTM)
$28.70
Debt/Equity
0.92x
Frequently Asked Questions
What is the PE ratio of ILMN?
The trailing twelve-month PE ratio of ILMN reflects how much investors pay per dollar of Illumina, Inc.'s earnings. This metric is most useful when compared to Medical - Diagnostics & Research peers and the company's own historical range.
Is ILMN overvalued based on PE ratio?
ILMN's PE of 28.9x combined with a PEG ratio of 0.22 provides a growth-adjusted perspective. A PEG below 1.0 suggests ILMN may be undervalued relative to its earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Diagnostics & Research, a DCF analysis may be more appropriate.
How do I value ILMN stock using PE ratio?
To value Illumina, Inc. using PE: (1) Compare the current PE (28.9x) against the Medical - Diagnostics & Research median to assess relative pricing, (2) check the PEG ratio (0.22) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of ILMN?
ILMN's PEG ratio is 0.22, calculated by dividing the PE ratio (28.9x) by the expected earnings growth rate. A PEG below 1.0 is traditionally considered a sign of undervaluation — the market may not be fully pricing in the growth potential. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for ILMN stock valuation?
PE ratio gives a quick relative read — how ILMN is priced versus Medical - Diagnostics & Research peers. DCF provides an absolute value based on projected free cash flows. For ILMN, with a strong ROE of 34.0%, both methods are worth using — PE for a market-relative check, DCF to stress-test whether fundamentals justify the price. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See ILMN DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value ILMN with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.